middle.news
How SomnoMed Hit $111.5M Revenue and Plans FDA-Backed Growth in FY26
2:17am on Saturday 30th of August, 2025 AEST
•
Healthcare
Read Story
How SomnoMed Hit $111.5M Revenue and Plans FDA-Backed Growth in FY26
2:17am on Saturday 30th of August, 2025 AEST
Key Points
FY25 revenue up 21.6% to $111.5 million
Positive EBITDA of $9.2 million and free cash flow of $0.8 million
FDA clearance obtained for Rest Assure® compliance monitoring
Over one million patients treated worldwide milestone achieved
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Somnomed (ASX:SOM)
OPEN ARTICLE